Skip to content
LATEST
Markets

MiNK gets $0.2m in first agenT-797 revenue

The clinical-stage cell-therapy company also cited ARPA-H program selection and expects U.S. dosing in a randomized Phase 2 ARDS trial before year-end.

MiNK gets $0.2m in first agenT-797 revenue

MiNK Therapeutics reported $0.2 million in first pre-commercial product revenue for the third quarter ended Sept. 30, 2026, in a securities filing released Nov. 12.

The update matters because MiNK, a clinical-stage cell-therapy company, ended the quarter with $7.5 million in cash, down from $8.8 million on June 30, while advancing its lead agenT-797 program.

The company said the revenue came from agenT-797 supplied through an international named-patient access program, where treating physicians request the investigational therapy for individually identified patients outside trials.

“In the third quarter, MiNK recognized its first pre-commercial product revenue from agenT-797 supplied on a paid, per-patient basis,” the company said in the filing exhibit.

Jennifer Buell, MiNK’s president and chief executive officer, linked the commercial access program with the company’s clinical work. “We now have a randomized trial running in critical illness, multiple clinical programs enrolling and a path toward pivotal development,” she said.

MiNK said its randomized, placebo-controlled Phase 2 trial, C-1300-02, is enrolling adults with acute lung injury and moderate-to-severe hypoxemic respiratory failure. The trial is testing agenT-797 plus standard of care against placebo plus standard of care in acute respiratory distress syndrome, or ARDS.

The company said U.S. dosing is expected before year-end 2026. The initial randomized stage is expected to enroll 124 patients, with an initial readout planned for the second half of 2027 and potential expansion under an adaptive design.

MiNK estimates about 93,000 U.S. patients annually fit its initial target group of ventilated, pneumonia-associated moderate-to-severe ARDS. The company said nearly four in 10 patients die within 28 days and no effective FDA-approved drug has been shown to reduce that mortality.

The company also said agenT-797 was selected in September as the therapeutic cell system for the Draper-led Reversible Ambient Biostabilization team under ARPA-H’s BioStabilization Systems program. MiNK said the program has up to $87 million in program-wide funding over four years for performers, not funding allocated solely to MiNK.

For the quarter, net loss was $2.6 million, or $0.50 a share, compared with $2.9 million, or $0.65 a share, in the prior-year period. General and administrative expense fell 44% to $1.0 million, while research and development expense rose to $1.8 million from $1.1 million.

The company said revenue from named-patient access may vary by quarter because it depends on physician requests and case-by-case regulatory authorizations. MiNK also said it is pursuing partnerships, licensing, non-dilutive funding and potential equity or debt financing to support the balance sheet and fund the randomized ARDS study through its readout.

Source: SEC Form 8-K exhibit and company press release, MiNK Therapeutics, Nov. 12, 2026.

Atlas360 reports health research and does not provide medical advice.

More stories

Latest news